| 2021 |
Florenzano P, Hartley IR, Jimenez M, Roszko K, Gafni RI, Collins MT. Tumor-induced osteomalacia. Calcif Tiss Int. January 2021;108(1):128-142. |
3 |
2 |
| 2022 |
Roszko KL, Hu TY, Guthrie LC, Brillante BA, Smith M, Collins MT, Gafni RI. PTH 1-34 replacement therapy has minimal effect on quality of life in patients with hypoparathyroidism. J Bone Miner Res. January 2022;37(1):68-77. |
1 |
0 |
| 2022 |
Ovejero D, Hartley IR, Diaz LFdC, Theng E, Li X, Gafni RI, Collins MT. PTH and FGF23 exert interdependent effects on renal phosphate handling: evidence from patients with hypoparathyroidism and hyperphosphatemic familial tumoral calcinosis treated with synthetic human PTH 1–34. J Bone Miner Res. February 2022;37(2):179-184. |
1 |
0 |
| 2022 |
Gafni RI, Langman CB, Guthrie LC, Brillante BA, James R, Yovetich NA, Boyce AM, Collins MT. Hypocitraturia is an untoward side effect of synthetic human parathyroid hormone (hPTH) 1–34 therapy in hypoparathyroidism that may increase renal morbidity. J Bone Miner Res. April 2022;37(4):818. |
0 |
0 |
| 2022 |
Roszko KL, Smith LMS, Sridhar AV, Roberts MS, Hartley IR, Gafni RI, Collins MT, Fox JC, Nemeth EF. Autosomal dominant hypocalcemia type 1: a systematic review. J Bone Miner Res. October 2022;37(10):1926-1935. |
0 |
0 |
| 2022 |
Hartley IR, Gafni RI, Roszko KL, Brown SM, de Castro LF, Saikali A, Ferreira CR, Gahl WA, Pacak K, Blau JE, Boyce AM, Salusky IB, Collins MT, Florenzano P. Determination of FGF23 levels for the diagnosis of FGF23-mediated hypophosphatemia. J Bone Miner Res. November 2022;37(11):2174-2185. |
0 |
0 |
| 2022 |
Mannstadt M, Cianferotti L, Gafni RI, Giusti F, Kemp EH, Koch CA, Roszko KL, Yao L, Guyatt GH, Thakker RV, Xia W, Brandi M-L. Hypoparathyroidism: genetics and diagnosis. J Bone Miner Res. December 2022;37(12):2615-2629. |
4 |
1 |